Marksans Pharma, a company in the Pharmaceuticals industry, reported revenue of ₹940 crore and net profit of ₹144 crore for the September 2026 quarter.
Marksans Pharma (NSE: MARKSANS) closed at ₹291.15 on 20 Nov 2026, up 50.8% over the past year. Its market capitalisation is ₹13,196 crore and it trades at 23.6 times earnings.
Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.